HOME >> BIOLOGY >> NEWS
'Modular' leukemia drug shows promise in early testing

COLUMBUS , Ohio -- A new type of engineered drug candidate has shown promise in treating chronic lymphocytic leukemia in both test tube and early animal tests, a new study shows.

The agent represents a new class of agents called small modular immunopharmaceuticals. Called CD37-SMIP, the agent targets a protein called CD37 on the surface of these leukemia cells.

The study shows that the agent can successfully attach to the protein on the leukemia cells and kill them. The agent works both by triggering the cells' self-destruction and by causing a particular class of immune cells to attack them.

In an animal model, the agent worked equally as well as the drug rituximab, now routinely used to treat chronic lymphocytic leukemia (CLL) patients. Rituximab targets a different protein on leukemia cells.

The study by researchers at the Ohio State University Comprehensive Cancer Center was published online in the journal Blood.

Our findings have significant implications for the treatment of CLL and related malignancies, says principal investigator John C. Byrd, director of the hematologic malignancies program at Ohio State 's James Cancer Hospital and Solove Research Institute.

Overall, Byrd says, the findings indicate that this could be an effective agent for treating CLL and other malignancies, such as non-Hodgkin's lymphoma and acute lymphoblastic leukemia when they have expression of the CD37 protein.

The laboratory portion of the study used CLL cells from patients, laboratory-grown non-Hodgkin's lymphoma cells and acute lymphocytic leukemia cells.

This research showed that the agent kills leukemia cells directly by triggering their self-destruction through the process of apoptosis.

The study also found that this self-destruction happens differently from how other drugs cause apoptosis. Most drugs cause cells to self-destruct by triggering a cell mechanism that requires en
'"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University
28-Jun-2007


Page: 1 2

Related biology news :

1. Adult survivors of childhood leukemia exercise less, worsening high risk for obesity and illness
2. Scientists gain important insights into acute promyelocytic leukemia
3. Researchers discover inherited mutation for leukemia
4. Inherited genes linked to toxicity of leukemia therapy
5. Unstable leukemia stem cells may predispose patients to drug resistance
6. Tree rings show elevated tungsten coincides with Nevada leukemia cluster
7. Cancer scientists create human leukemia process to map how disease begins, progresses
8. Antioxidant found in many foods and red wine is potent and selective killer of leukemia cells
9. Knocking out survival protein could aid leukemia treatment
10. Massey researchers induce cell death in leukemia
11. Progress toward a targeted therapy for a specific form of leukemia

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2019)... ... July 10, 2019 , ... Inference Solutions , ... organizations, today announced its role in Pizza Hut Australia’s digital transformation initiative ... franchisees. A key part of this initiative is implementation of an automated call-steering ...
(Date:7/9/2019)... (PRWEB) , ... July 08, 2019 , ... ... company’s footprint in the biotechnology hub of Cambridge, MA. This expansion strengthens KMK’s ... primary market research , and sales force effectiveness consulting for the ...
(Date:7/5/2019)... MOUNTAIN VIEW, Calif. (PRWEB) , ... July 05, ... ... is partnering with Microsoft to bring its patented Tractus™ Platform to governments around ... solution will bring cutting edge technology and point of care solutions to operating ...
Breaking Biology News(10 mins):
(Date:5/8/2019)... ... ... Standing at 16.2 hands, Atlas is on the large side for a Quarter Horse. ... among other activities. When loping around a corner in late 2017, Atlas tripped and ... to only being able to walk. Fortunately Atlas’ owner, Kelly, sought the opinion of ...
(Date:5/4/2019)... ... May 03, 2019 , ... ... President of the Dakila Pesquisas Association, the scientist and ufologist Urandir Fernandes de ... Brasília (DF). Urandir detailed the results of some research carried out by the ...
(Date:5/2/2019)... ... April 30, 2019 , ... ... ISO 9001:2015 standard, REPROCELL USA Inc. has demonstrated its ability to provide ... USA Inc. aims to enhance customer satisfaction through the effective implementation of ...
(Date:5/2/2019)... ... May 02, 2019 , ... Stay on top of current hot topics through ... Access to all webinars is free, so be sure to register today to save ... http://www.xtalks.com to see our upcoming webinars: , CLINICAL TRIALS , May 7 ...
Breaking Biology Technology:
Cached News: